文献速递心境障碍

双相障碍精准医学的进展:机制与分子

Advances toward precision medicine for bipolar disorder: mechanisms & molecules.
PubMed 文献 · Mol Psychiatry · 2020-07-07

本文综述双相障碍精准医学的进展,指出尽管锂盐仍是急性期和预防复发的主要药物,但对其作用机制理解有限且缺乏经验证的细胞和动物模型,阻碍了更有效、副作用更少的心境稳定剂研发。人类遗传学研究证实双相障碍具有复杂多基因风险架构,并与其它重性神经精神障碍重叠,结合神经生物学、神经药理学、无创神经调控和临床试验设计的进步,有望开发针对病理生理根源的新型治疗策略。

要点

  • 锂盐仍是双相障碍急性期和预防复发的主要药物,但机制不明限制新药研发。
  • 双相障碍风险架构为复杂多基因,与其它重性神经精神障碍重叠。
  • 急性双相抑郁的有效治疗仍不足,需针对分子机制和神经环路开发新策略。

核心结论

  • 双相障碍精准医学需基于明确分子机制和神经环路开发针对病理生理根源的新型治疗策略。

研究设计与样本

  • 本文为综述,回顾双相障碍治疗相关进展并概述转化神经科学领域的主要挑战。

主要发现

  • 锂盐广泛用于急性治疗和预防复发性躁狂/轻躁狂及抑郁,但作用机制理解有限。
  • 缺乏经验证的细胞和动物模型阻碍了更有效、副作用更少的心境稳定剂发现。
  • 躁狂新药研发有进展,但急性双相抑郁的有效治疗仍不充分。
  • 大规模人类遗传学研究证实双相障碍风险架构为复杂多基因,并与其它重性神经精神障碍重叠。

临床怎么用

  • 锂盐仍是双相障碍急性期和预防复发的主要药物。
  • 急性双相抑郁治疗选择有限,需关注新药研发进展。

局限性

  • 对锂盐调节情感行为的机制理解有限。
  • 缺乏经验证的细胞和动物模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Given its chronicity, contribution to disability and morbidity, and prevalence of more than 2%, the effective treatment, and prevention of bipolar disorder represents an area of significant unmet medical need. While more than half a century has passed since the introduction of lithium into widespread use at the birth of modern psychopharmacology, that medication remains a mainstay for the acute treatment and prevention of recurrent mania/hypomania and depression that characterize bipolar disorder. However, the continued limited understanding of how lithium modulates affective behavior and lack of validated cellular and animal models have resulted in obstacles to discovering more effective mood stabilizers with fewer adverse side effects. In particular, while there has been progress in developing new pharmacotherapy for mania, developing effective treatments for acute bipolar depression remain inadequate. Recent large-scale human genetic studies have confirmed the complex, polygenic nature of the risk architecture of bipolar disorder, and its overlap with other major neuropsychiatric disorders. Such discoveries have begun to shed light on the pathophysiology of bipolar disorder. Coupled with broader advances in human neurobiology, neuropharmacology, noninvasive neuromodulation, and clinical trial design, we can envision novel therapeutic strategies informed by defined molecular mechanisms and neural circuits and targeted to the root cause of the pathophysiology. Here, we review recent advances toward the goal of better treatments for bipolar disorder, and we outline major challenges for the field of translational neuroscience that necessitate continued focus on fundamental research and discovery.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Haggarty SJ, Karmacharya R, Perlis RH, et al. Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Mol Psychiatry. 2020. PMID: 32636474. doi:10.1038/s41380-020-0831-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。